Kazia Therapeutics Limited
KZIA
$9.15
$0.242.69%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
6/18/2025
-
GuruFocus
6/11/2025
-
GuruFocus
6/11/2025
-
Benzinga
6/11/2025
-
MarketBeat
6/11/2025
-
GuruFocus
6/11/2025
-
GuruFocus
6/11/2025
-
TipRanks Financial Blog
6/11/2025
-
The Fly
6/11/2025
-
TipRanks Financial Blog
6/11/2025
-
The Fly
6/11/2025
-
GuruFocus
6/11/2025
-
GuruFocus
6/11/2025
-
GuruFocus
6/11/2025
-
The Fly
6/11/2025
-
PR Newswire
6/5/2025
-
GuruFocus
6/5/2025
-
GuruFocus
6/5/2025
-
GuruFocus
6/5/2025
-
The Fly
6/5/2025
-
PR Newswire
5/23/2025
-
TipRanks Financial Blog
5/15/2025
-
GuruFocus
5/15/2025
-
GuruFocus
5/15/2025
-
PR Newswire
4/16/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, June 10, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Nov 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
61 2 9472 4101
Address
Three International Towers
Level 24 - 300 Barangaroo Avenue
Sydney, NSW 2000
Level 24 - 300 Barangaroo Avenue
Sydney, NSW 2000
Country
Year Founded
Business Description
Sector
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule...
more